NCT05810961

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)

A Multicenter, Randomized, Double-blinded, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: argenx · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with primary membranous nephropathy (pMN).

Detailed description

To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with primary membranous nephropathy (pMN).The study comprises a maximum 4-week screening period, a 24-week treatment period, and an 8-week follow-up period

Conditions

• Membranous Nephropathy

Interventions

Type	Name	Description
BIOLOGICAL	efgartigimod IV	infusion of efgartigimod
OTHER	placebo	infusion of placebo

Timeline

• Start date: 2023-02-20
• Primary completion: 2024-08-05
• Completion: 2024-08-05
• First posted: 2023-04-13
• Last updated: 2024-11-22

Locations

31 sites across 1 country: China